Drug eluting stents to soon become more affordable

The National Pharmaceutical Pricing Authority (NPPA) on Monday brought down the prices of the most commonly used drug eluting coronary stents, used to clear blockages in the arteries. T

Published: 13th February 2018 02:40 AM  |   Last Updated: 13th February 2018 04:53 AM   |  A+A-

Express News Service

BENGALURU:  The National Pharmaceutical Pricing Authority (NPPA) on Monday brought down the prices of the most commonly used drug eluting coronary stents, used to clear blockages in the arteries. The maximum price has been cut from `30,180 to `27,890. But it has hiked the prices of bare metal stent prices from `7,400 to `7,660. According to the regulator, hospitals will need to display the prices of accessories like catheters and balloons separately in the bill along with their brand names. Patients will have an option to get a stent and accessories from outside the establishment.

It has also invited comments to check the cost of guide wire, balloon catheters and guiding catheters which are being sold at 15% to 400% margins. Currently, only 8% trade margin has been allowed in stents. Companies which want to discontinue their stents will have to give six months’ notice, according to NPPA. The new rates will be applicable till March 31, 2019. Dr C N Manjunath, Director, Jayadeva Institute of Cardiovascular Sciences, said, “Patients are going to lose good quality stents, no doubt about it. There’s absolutely no benefit in further slashing the prices. Now we have to just use whatever drug eluting stenst are available in the market.”

REACTING to the cut in the prices of drug eluting stents, AdvaMed, an association representing stent manufacturers, said in a statement, “This notification disregards stakeholder representations and goes against patient interest by failing to reward innovative technologies thereby limiting patient choice for current and future medical device innovations.”

“A recent study by IQVIA, commissioned by AdvaMed, clearly shows that price controls have not led to lower procedure costs – where patients need relief the most. Furthermore, patients have not gained greater access as indicated by the fact that angioplasty treatments have not increased in any meaningful way as a result of this policy. To achieve real on-the-ground impact, we hoped that the government would consider alternate approaches such as Trade Margin Rationalization and differential pricing that have the dual effect of benefiting patients while preserving the environment for innovation and investment in India,” it said.

Dr K K Agarwal, former IMA president, said, “Bare metal stents have a significantly higher rate of restenosis and the need for target vessel revascularization compared with all drug-eluting stents (DES). For most patients undergoing percutaneous coronary intervention with stenting, one recommends current-generation DES rather than BMS.”


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp